BACKGROUND: Inhibition of cyclin-dependent kinases (CDKs) has recently emerged as an interesting approach to treat human malignancies. This was explored in human leiomyosarcoma (LMS) lines, which represent a tumour associated with poor survival, chemo-unresponsiveness and deregulation of cell cycle components. MATERIALS AND METHODS: Using isobologram analysis with MTT chemosensitivity testing, the effects of the CDK inhibitor seliciclib (CYC202, R-roscovitine) when used alone or in combination with paclitaxel was studied in uterine cancer cell lines. Apoptotic endpoints were also examined via Annexin V assay using flow cytometry and Western blotting. RESULTS: Overall seliciclib combined with paclitaxel proved synergistic for all cell lines. This was concomitant with an enhanced apoptotic effect and downregulation of the LAP survivin. CONCLUSION: Our data support the use of seliciclib as part of combination therapy for uterine cancer.
BACKGROUND: Inhibition of cyclin-dependent kinases (CDKs) has recently emerged as an interesting approach to treat humanmalignancies. This was explored in humanleiomyosarcoma (LMS) lines, which represent a tumour associated with poor survival, chemo-unresponsiveness and deregulation of cell cycle components. MATERIALS AND METHODS: Using isobologram analysis with MTT chemosensitivity testing, the effects of the CDK inhibitor seliciclib (CYC202, R-roscovitine) when used alone or in combination with paclitaxel was studied in uterine cancer cell lines. Apoptotic endpoints were also examined via Annexin V assay using flow cytometry and Western blotting. RESULTS: Overall seliciclib combined with paclitaxel proved synergistic for all cell lines. This was concomitant with an enhanced apoptotic effect and downregulation of the LAP survivin. CONCLUSION: Our data support the use of seliciclib as part of combination therapy for uterine cancer.
Authors: Jonas Cicenas; Karthik Kalyan; Aleksandras Sorokinas; Edvinas Stankunas; Josh Levy; Ingrida Meskinyte; Vaidotas Stankevicius; Algirdas Kaupinis; Mindaugas Valius Journal: Ann Transl Med Date: 2015-06
Authors: Johannes Tobias Thiel; Adrien Daigeler; Jonas Kolbenschlag; Katarzyna Rachunek; Sebastian Hoffmann Journal: Cancers (Basel) Date: 2022-07-12 Impact factor: 6.575